Monkeypox Vaccines – Golden Opportunity Or False Dawn?
Moderna, Tonix Pharma Show Interest
While Moderna plans preclinical studies and Tonix Pharma’s candidate is to enter trials in H1, Bavarian Nordic is seeking US and Indian manufacturing partners for its approved monkeypox vaccine. Scrip examines if the disease presents an opportunity for vaccine makers, like COVID-19 did or it could go the H1N1 way
You may also be interested in...
With the world’s first exclusively intranasal COVID-19 vaccine against COVID-19 getting restricted use approval in India, Bharat Biotech/Washington University St. Louis offer an easy-to-use immunization option. But is it too little too late?
Deal Snapshot: The contract for Tembexa, which builds on an existing deal between Chimerix and Emergent BioSolutions, illustrates lucrative potential opportunities for emergency preparedness.
The US FDA's Peter Marks also says the intradermal dose-sparing plan was motivated by concern over city and state one-dose strategies.